vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and SILICOM LTD. (SILC). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $61.9M, roughly 1.3× SILICOM LTD.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -18.5%, a 25.4% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 6.6%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-3.3M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Silicom Ltd. is a publicly traded company, headquartered in Israel, that specializes in the design, manufacture and marketing of connectivity solutions for a range of servers and server-based systems. Its shares are listed on the NASDAQ Global Market and on the Tel Aviv Stock Exchange. Silicom is a member of the RAD Group family of companies.
BLLN vs SILC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $61.9M |
| Net Profit | $5.7M | $-11.5M |
| Gross Margin | 69.9% | 30.6% |
| Operating Margin | 11.5% | -19.8% |
| Net Margin | 6.8% | -18.5% |
| Revenue YoY | 117.4% | 6.6% |
| Net Profit YoY | 138.3% | 16.3% |
| EPS (diluted) | $0.10 | $-2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $61.9M | ||
| Q3 25 | $83.5M | — | ||
| Q4 24 | — | $58.1M | ||
| Q3 24 | $38.4M | — |
| Q4 25 | — | $-11.5M | ||
| Q3 25 | $5.7M | — | ||
| Q4 24 | — | $-13.7M | ||
| Q3 24 | $-14.9M | — |
| Q4 25 | — | 30.6% | ||
| Q3 25 | 69.9% | — | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | 52.6% | — |
| Q4 25 | — | -19.8% | ||
| Q3 25 | 11.5% | — | ||
| Q4 24 | — | -22.8% | ||
| Q3 24 | -32.9% | — |
| Q4 25 | — | -18.5% | ||
| Q3 25 | 6.8% | — | ||
| Q4 24 | — | -23.6% | ||
| Q3 24 | -38.8% | — |
| Q4 25 | — | $-2.01 | ||
| Q3 25 | $0.10 | — | ||
| Q4 24 | — | $-2.28 | ||
| Q3 24 | $-1.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $42.1M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $117.5M |
| Total Assets | $327.5M | $152.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $42.1M | ||
| Q3 25 | $195.2M | — | ||
| Q4 24 | — | $72.1M | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | $117.5M | ||
| Q3 25 | $-239.5M | — | ||
| Q4 24 | — | $127.8M | ||
| Q3 24 | $-242.9M | — |
| Q4 25 | — | $152.2M | ||
| Q3 25 | $327.5M | — | ||
| Q4 24 | — | $150.4M | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-2.2M |
| Free Cash FlowOCF − Capex | $6.5M | $-3.3M |
| FCF MarginFCF / Revenue | 7.7% | -5.4% |
| Capex IntensityCapex / Revenue | 8.8% | 1.9% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $13.8M | — | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | — |
| Q4 25 | — | $-3.3M | ||
| Q3 25 | $6.5M | — | ||
| Q4 24 | — | $17.4M | ||
| Q3 24 | — | — |
| Q4 25 | — | -5.4% | ||
| Q3 25 | 7.7% | — | ||
| Q4 24 | — | 29.9% | ||
| Q3 24 | — | — |
| Q4 25 | — | 1.9% | ||
| Q3 25 | 8.8% | — | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
SILC
Segment breakdown not available.
